JPRN-UMIN000016213已完成未知
A feasibility study of dose-dense epirubicin and cyclophosphamide for primary breast cancer in neoadjuvant and adjuvant setting - A feasibility study of dose-dense chmotherapy for primary breast cancer
agoya University Hospital0 个研究点目标入组 50 人开始时间: 2015年1月28日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •Patients with active infection need to treat systemic therapy, nursing, mental disorder, or other uncontrolled medical conditions are excluded.
研究者
相似试验
已完成
3 期
IBCSG 15-95 - Randomised trial of high-dose epirubicin and cyclophosphamide x 3 supported by peripheral blood progenitor cells versus anthracycline and cyclophosphamide x 4 followed by cyclophosphamide, methotrexate, and 5-fluoruracil x 3 as adjuvant treatment for high risk operable stage II and stage III breast cancer in premenopausal and young postmenopausal (<=65 yrs) patientsCancer - BreastBreast CancerACTRN12607000025437International Breast Cancer Study Group300
进行中（未招募）
1 期
Randomized trial of sequential epirubicin and docetaxel against docetaxel in patients with early operable breast cancer. - READ TOP2AWomen with operable breast cancer and increased risk of recurrenceEUCTR2007-003126-15-DKDBCG1,932
招募中
2 期
Feasibility study of dose dense chemotherapy for primary breast cancer patientsBreast cancerJPRN-UMIN000026954Mie University Hospital30
进行中（未招募）
不适用
Dose-dense treatment with gemcitabine, epirubicin and paclitaxel GET combination in advanced breast cancer a phase II parallel studyWomen with advanced metastatic breast cancer, not previously treated with anthracyclines or taxanesMedDRA version: 6.1Level: HLTClassification code 10006292EUCTR2005-003582-16-ITAZIENDA OSPEDALIERA POLICLINICO DI MODENA
已完成
不适用
Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: FeasibilityAdenocarcinoma of the BreastBreast CancerNCT00617370Memorial Sloan Kettering Cancer Center38